US Bancorp DE Has $88,000 Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

US Bancorp DE trimmed its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 61.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,309 shares of the company’s stock after selling 5,227 shares during the quarter. US Bancorp DE’s holdings in Edgewise Therapeutics were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Quest Partners LLC raised its holdings in Edgewise Therapeutics by 418.7% in the 3rd quarter. Quest Partners LLC now owns 9,035 shares of the company’s stock worth $241,000 after acquiring an additional 7,293 shares during the period. Meeder Asset Management Inc. lifted its position in shares of Edgewise Therapeutics by 69.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,307 shares of the company’s stock worth $88,000 after purchasing an additional 1,361 shares during the last quarter. Intech Investment Management LLC bought a new stake in Edgewise Therapeutics during the 3rd quarter valued at approximately $531,000. Glenmede Trust Co. NA acquired a new stake in Edgewise Therapeutics in the 3rd quarter valued at approximately $483,000. Finally, Acuta Capital Partners LLC bought a new position in Edgewise Therapeutics in the 3rd quarter worth approximately $1,681,000.

Edgewise Therapeutics Stock Up 3.0 %

NASDAQ:EWTX opened at $26.43 on Tuesday. The firm has a market capitalization of $2.52 billion, a PE ratio of -17.62 and a beta of 0.22. Edgewise Therapeutics, Inc. has a 12-month low of $14.90 and a 12-month high of $38.12. The firm has a 50-day moving average price of $26.68 and a 200 day moving average price of $28.22.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its earnings results on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). On average, research analysts expect that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current year.

Insider Buying and Selling at Edgewise Therapeutics

In other news, insider Marc Semigran sold 29,709 shares of Edgewise Therapeutics stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total value of $882,060.21. Following the completion of the transaction, the insider now owns 6,716 shares in the company, valued at approximately $199,398.04. The trade was a 81.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Alan J. Russell sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $27.37, for a total value of $2,737,000.00. Following the completion of the transaction, the insider now directly owns 14,863 shares in the company, valued at $406,800.31. The trade was a 87.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 164,545 shares of company stock worth $4,605,305 over the last three months. Company insiders own 24.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on EWTX. Royal Bank of Canada reissued an “outperform” rating and issued a $56.00 price objective on shares of Edgewise Therapeutics in a research report on Tuesday, March 4th. Scotiabank assumed coverage on shares of Edgewise Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. Evercore ISI boosted their price objective on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Truist Financial upped their price objective on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Finally, Stifel Nicolaus started coverage on Edgewise Therapeutics in a report on Wednesday, January 22nd. They issued a “hold” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.38.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.